The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia.

abstract：:A prospective randomized double-blind trial was performed comparing conventional low-dose heparin with a LMWH fragment (Kabi 2165, Fragmin) for thromboprophylaxis in elective general abdominal surgical patients. The first dose of the fragment was given in the evening before surgery, and thereafter every evening. There...

journal_title：Seminars in thrombosis and hemostasis

authors： Bergqvist D,Burmark US,Frisell J,Guilbaud O,Hallböök T,Horn A,Lindhagen A,Ljungner H,Ljungström KG,Mätzsch T

更新日期：1990-10-01 00:00:00

abstract：:Recombinant thrombolytic peptides are mainly represented by recombinant forms of tissue plasminogen activator (t-PA), a proteolytic enzyme that catalyzes the conversion of plasminogen into active plasmin, which then functions to dissolve clots. The three clinically relevant recombinant thrombolytic peptides are altepl...

journal_title：Seminars in thrombosis and hemostasis

authors： Campbell J,Hilleman D

更新日期：2010-07-01 00:00:00

abstract：:Three commercial prothrombin complex concentrates (PCC) were compared in vitro. Differences in the activities or contents, respectively, of the PCC factors FII, FVII, FIX, FX and the proteins C, S, and Z (antigen) in particular were found. Global tests of activated factors did not reveal marked differences between the...

journal_title：Seminars in thrombosis and hemostasis

authors： Römisch J,Bonik K,Müller HG

更新日期：1998-01-01 00:00:00

abstract：:Hemophilia A and B gene therapy requires long-term and stable expression of coagulation factor VIII (FVIII) or factor IX (FIX), respectively, and would need to compare favorably with protein replacement therapy. Onco-retroviral and lentiviral vectors are attractive vectors for gene therapy of hemophilia. These vectors...

journal_title：Seminars in thrombosis and hemostasis

authors： Van Damme A,Chuah MK,Collen D,VandenDriessche T

更新日期：2004-04-01 00:00:00

abstract：:Thrombotic events are uncommon disorders in childhood but increasingly recognized due to the progress made in the understanding of the hemostasis system and the importance of thromboembolic disorders in children. Multiple clinical underlying conditions and prothrombotic disorders contribute to the development of throm...

journal_title：Seminars in thrombosis and hemostasis

authors： Tormene D,Gavasso S,Rossetto V,Simioni P

更新日期：2006-10-01 00:00:00

abstract：:Arterial and venous thromboses are sustained by development of intraluminal thrombi, respectively, within the venous and arterial systems. The composition and structure of arterial and venous thrombi have been historically considered as being very different. Arterial thrombi (conventionally defined as "white") have be...

journal_title：Seminars in thrombosis and hemostasis

authors： Lippi G,Favaloro EJ

更新日期：2018-04-01 00:00:00

abstract：:The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecu...

journal_title：Seminars in thrombosis and hemostasis

authors： Alban S

更新日期：2001-10-01 00:00:00

abstract：:Current concepts of the cause, pathophysiologic mechanisms, diagnosis, and management of acute and chronic DIC have been discussed. Considerable attention has been devoted to interrelationships that have remained confusing. Only by clearly understanding these pathophysiologic interrelationships can the clinician and l...

journal_title：Seminars in thrombosis and hemostasis

authors： Bick RL

更新日期：1988-10-01 00:00:00

abstract：:Systolic heart failure is a common syndrome whose incidence is expected to increase. Several treatment modalities, such as beta-blockers and angiotensin-converting enzyme inhibitors, improve survival. Whether antithrombotic treatment is effective remains to be elucidated, although observations suggest a prothrombotic ...

journal_title：Seminars in thrombosis and hemostasis

authors： de Peuter OR,Kok WE,Torp-Pedersen C,Büller HR,Kamphuisen PW

更新日期：2009-07-01 00:00:00

abstract：:Despite numerous past and ongoing efforts, there remains significant variation in results from assays for the major antiphospholipid antibodies (aPL), namely anticardiolipin (aCL), anti-beta2 glycoprotein I (anti-beta2GPI), and lupus anticoagulant (LA). There is therefore a need to produce comprehensive guidelines on ...

journal_title：Seminars in thrombosis and hemostasis

authors： Wong RC,Favaloro EJ

更新日期：2008-06-01 00:00:00

abstract：:Statins are approved by the Food and Drug Administration (FDA) for the treatment of hypercholesterolemia and have shown remarkable activity in preventing cardiovascular morbidity and mortality. The versatility of statins is increasingly being appreciated, however, and lowering cholesterol is only one attribute among m...

journal_title：Seminars in thrombosis and hemostasis

authors： Splichal JE,Stamm JA,Ornstein DL

更新日期：2003-06-01 00:00:00

abstract：:In severe infection and sepsis, activation of coagulation frequently occurs, which contributes to the development of multiple organ dysfunction. Factor V Leiden is a relatively common mutation resulting in a mild prohemostatic state and consequently with an increased tendency to develop thrombosis. Hypothetically, pat...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,Schouten M,van't Veer C,van der Poll T

更新日期：2011-11-01 00:00:00

abstract：:Atrial fibrillation (AF) can be secondary to acute pulmonary embolism (PE). This study aimed to investigate the prognostic impact of new-onset AF on patients with acute PE. In this study, 4,288 consecutive patients who were diagnosed with acute PE were retrospectively screened. In total, 77 patients with acute PE and ...

journal_title：Seminars in thrombosis and hemostasis

authors： Tang RB,Jing YY,Xu ZY,Dong JZ,Du X,Wu JH,Yu RH,Long DY,Ning M,Sang CH,Jiang CX,Bai R,Liu N,Wen SN,Li SN,Chen X,Huang ST,Cui YK,Ma CS

更新日期：2020-11-01 00:00:00

abstract：:Most patients with atrial fibrillation need anticoagulant treatment with vitamin K antagonists for prevention of thromboembolism, in particular ischemic stroke. Many studies show the efficacy of this treatment but also that it is difficult to keep patients who use vitamin K antagonists in the proper treatment range. B...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M,de Peuter OR,Kamphuisen PW

更新日期：2009-09-01 00:00:00

abstract：:Self-control and self-management of oral anticoagulant therapy have become more and more attractive for patients undergoing long-term treatment. In our training center, we examined 50 patients who took part in a standardized training course for self-management. Patients (36 men, 14 women) were preselected according to...

journal_title：Seminars in thrombosis and hemostasis

authors： Mörsdorf S,Erdlenbruch W,Taborski U,Schenk JF,Erdlenbruch K,Novotny-Reichert G,Krischek B,Wenzel E

更新日期：1999-01-01 00:00:00

abstract：:Heparanase is an endo-β-glucuronidase that enzymatically cleaves heparan sulfates (HS) and heparan sulfate proteoglycan (HSPG) structures. Heparanase expression levels by tumors were correlated with cell invasion, angiogenic activity, and poor prognosis. Heparanase can also possess pro-tumorigenic effects independent ...

journal_title：Seminars in thrombosis and hemostasis

authors： Gerber U,Hoß SG,Shteingauz A,Jüngel E,Jakubzig B,Ilan N,Blaheta R,Schlesinger M,Vlodavsky I,Bendas G

更新日期：2015-03-01 00:00:00

abstract：:Neutrophils have long been known as innate immune cells that phagocytose and kill pathogens and mount inflammatory responses protecting the host from infection. In the past decades, new aspects of neutrophils have emerged unmasking their importance not only in inflammation but also in many pathological conditions incl...

journal_title：Seminars in thrombosis and hemostasis

authors： Demers M,Wagner DD

更新日期：2014-04-01 00:00:00

abstract：:Several LMWHs are currently available for commercial use. The development status of each of these products in the area of prophylaxis, therapeutics, and other indications is given in Table 4. Enoxaparin and Fraxiparin appear to be the most developed LMWHs in both the surgical and medical areas. Many well-designed clin...

journal_title：Seminars in thrombosis and hemostasis

authors： Fareed J,Walenga JM,Hoppensteadt D,Borris LC,Lassen MR

更新日期：1991-01-01 00:00:00

abstract：:In this article, three cases, with antithrombin (AT) abnormality "Toyama" (type IIb), AT abnormality "Aomori" (type IIa), and congenital AT deficiency (type I) with pregnancy and delivery managed with administration of both AT concentrates and low-molecular-weight heparin, are described. Additionally, a case of AT-pro...

journal_title：Seminars in thrombosis and hemostasis

authors： Sakuragawa N

更新日期：1997-01-01 00:00:00

abstract：:Asymptomatic pulmonary embolism (PE) is present in at least one-third of patients with deep venous thrombosis (DVT). However, knowledge about its influence on the prognosis of patients is limited. The aim of this study was to assess the prognostic impact of asymptomatic PE in patients with DVT and to explore risk fact...

journal_title：Seminars in thrombosis and hemostasis

authors： Boc A,Vene N,Košmelj K,Mavri A

更新日期：2017-02-01 00:00:00

abstract：:Coagulation factor XII (FXII), formerly known as Hageman factor, is a plasma glycoprotein which exerts a kaleidoscope of biological functions, including the initiation of the intrinsic pathway of blood coagulation, the activation of the kallikrein-kinin system, and the generation of bradykinin and angiotensin. The lar...

journal_title：Seminars in thrombosis and hemostasis

authors： Danese E,Montagnana M,Lippi G

更新日期：2016-09-01 00:00:00

abstract：:Protamine sulfate has been used for many years to reverse the effects of unfractionated heparin, but it can cause hemodynamic changes and other serious side effects. Platelet factor 4 (PF4) is a naturally occurring protein synthesized in megakaryocytes and eventually stored in the alpha granules of platelets for later...

journal_title：Seminars in thrombosis and hemostasis

authors： Mixon TA,Dehmer GJ

更新日期：2004-06-01 00:00:00

abstract：:Cancer often leads to the activation of coagulation, manifesting as disseminated intravascular coagulation (DIC) in its most extreme form. DIC is characterized by systemic intravascular coagulation activation (leading to deposition of intravascular platelets and fibrin) and simultaneous consumption of coagulation prot...

journal_title：Seminars in thrombosis and hemostasis

authors： Levi M

更新日期：2019-06-01 00:00:00

abstract：:CD34 (+) progenitor cells are a promising source of regeneration in atherosclerosis or ischemic heart disease. However, as recently published, CD34(+) progenitor cells have the potential to differentiate not only into endothelial cells but also into foam cells upon interaction with platelets. The mechanism of platelet...

journal_title：Seminars in thrombosis and hemostasis

authors： Seizer P,Schiemann S,Merz T,Daub K,Bigalke B,Stellos K,Müller I,Stöckle C,Müller K,Gawaz M,May AE

更新日期：2010-03-01 00:00:00

abstract：:Seminal vesicle protein 4 (SV-IV) is a highly flexible molecule that in aqueous solution behaves as a concentration-dependent self-associating system in which the degree of association (monomer <--> dimer <--> trimer equilibrium) seems to be related to its biological activities. This review reports the functional role...

journal_title：Seminars in thrombosis and hemostasis

authors： Metafora S,Esposito C,Caputo I,Lepretti M,Cassese D,Dicitore A,Ferranti P,Stiuso P

更新日期：2007-02-01 00:00:00

abstract：:Molecular linkages between von Willebrand factor (VWF) and the alternative complement pathway (AP) have recently been discovered. Endothelial cell (EC)-anchored ultra-large (UL) VWF multimeric strings function as an activating surface for the AP. C3 (in active C3b form) binds to the EC-anchored ULVWF strings, and prom...

journal_title：Seminars in thrombosis and hemostasis

authors： Turner N,Nolasco L,Nolasco J,Sartain S,Moake J

更新日期：2014-07-01 00:00:00

abstract：:The risk for arteriosclerosis and thrombosis of patients with severe hyperhomocysteinemia is reduced by homocysteine-lowering therapy. Whether this is the case in patients with mild hyperhomocysteinemia remains to be proved. Another challenge for researchers is to establish a satisfying pathological mechanism of the v...

journal_title：Seminars in thrombosis and hemostasis

authors： Blom HJ

更新日期：2000-01-01 00:00:00

abstract：:Morbidity and mortality for cardiovascular disease are likely to be lower in patients with hemophilia than in the general male population. However, their clinical impact is increasing in parallel with the increase of life expectancy due to modern safe replacement treatments and the improvement of comprehensive care of...

journal_title：Seminars in thrombosis and hemostasis

authors： Coppola A,Tagliaferri A,Franchini M

更新日期：2010-02-01 00:00:00

abstract：: ...

journal_title：Seminars in thrombosis and hemostasis

authors： Favaloro EJ

更新日期：2019-02-01 00:00:00

abstract：:Persons with hematologic malignancies bleed for a variety of reasons, including alterations in platelet function and numbers, clotting factor deficiencies, circulating anticoagulants, and defects in vascular integrity. The management of bleeding begins with a full characterization of the hemostatic defect. Vitamin K d...

journal_title：Seminars in thrombosis and hemostasis

authors： Green D

更新日期：2007-06-01 00:00:00